Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: Evidence for the involvement of sympathetic regulation

Schizophrenia Bulletin

Volumn 36, Issue 2, 2010, Pages 410-418

  Savoy, Yvette E ^a   Ashton, Michael A ^a   Miller, Matthew W ^a   Nedza, Frank M ^a   Spracklin, Douglas K ^a   Hawthorn, Mark H ^a   Rollema, Hans ^a   Matos, F Fatima ^a   Hajos Korcsok, Eva ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotic; Hyperglycemia; Insulin; Mouse

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; HALOPERIDOL; HEXAMETHONIUM; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; YOHIMBINE; ZIPRASIDONE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD SAMPLING; C57BL 6 MOUSE; CD 1 MOUSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; FVB N MOUSE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIONIC BLOCKERS; GLUCOSE TOLERANCE TEST; HEXAMETHONIUM; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN; MALE; MICE; SYMPATHETIC NERVOUS SYSTEM; YOHIMBINE;

EID: 77749254670     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn104     Document Type: Article

References (41)

1. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:36-46.
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Con-sensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
4. Also published in J Clin Psychiatry. 2004;65:267-272.
5. Erle G, Basso M, Federspil G, Sicolo N, Scandellari C. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol. 1977;11:15-18.
6. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:1-93.
7. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998;59:294-299.
8. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-as-sociated diabetes. Am J Med. 2001;111:716-723.
9. Wilson DR, D'Souza L, Sarkar N, Newton M, Hammond C. New-onset diabetes and ketoacidosis with atypical antipsy-chotics. Schizophr Res. 2003;59:1-6.
10. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes. 2005;54:1552-1558.
11. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsy-chotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289-297.
12. Nakadate T, Kubota K, Muraki T, Kato R. Mechanism of chlorpromazine action on plasma glucose and cyclic AMP levels. Eur J Pharmacol. 1980;64:107-113. (Pubitemid 10071955)
13. Nakadate T, Muraki T, Kato R. Effects of alpha-and beta-adrenergic blockers on chlorpromazine-induced elevation of plasma glucose and cyclic AMP in fed mice. Jpn J Pharmacol. 1980;30:199-206.
14. Bugajski J, Lech J. Effects of neuroleptics on blood glucose, free fatty acids and liver glycogen levels in the rat. Pol J Pharmacol Pharm. 1979;31:45-58.
15. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav. 2003;75:255-260.
16. Johnson DE, Nedza FM, Spracklin DK, et al. The role of muscarinic receptor antagonism in antipsychotic-induced hip-pocampal acetylcholine release. Eur J Pharmacol. 2005;506:209-219.
17. Maurer TS, Debartolo DB, Tess DA, Scott DO. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos. 2005;33:175-181.
18. Shusterman V, Usiene I, Harrigal C, et al. Strain-specific patterns of autonomic nervous system activity and heart failure susceptibility in mice. Am J Physiol Heart Circ Physiol. 2002;282:2076-2083.
19. Haluzik M, Colombo C, Gavrilova O, et al. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology. 2004;145:3258-3264.
20. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988;247: 661-670.
21. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-345.
22. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregula-tion with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862-871.
23. Ghafghazi T, Miya TS, Mennear JH, Chalmers RK. Chlor-promazine and epinephrine hyperglycemic mechanisms. J Pharm Sci. 1968;57:1690-1693.
24. Fujimori K, Iwamoto T. Mechanisms of hyperglycemic response to chlorpromazine administered into lateral ventricle in rats. II. Secretion of epinephrine from adrenal medulla. Neuropharmacology. 1974;13:255-260.
25. Breier A, Buchanan RW, Waltrip RW, Listwak S, Holmes C, Goldstein DS. The effect of clozapine on plasma norepineph-rine: relationship to clinical efficacy. Neuropsychopharmacol-ogy. 1994;10:1-7.
26. Brown AS, Gewirtz G, Harkavy-Friedman J, et al. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology. 1997;17:317-325.
27. See RE, Fido AA, Maurice M, Ibrahim MM, Salama GM. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biol Psychiatry. 1999;45:1653-1656.
28. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia. 2000;43:533-549.
29. Elias AN, Hofflich H. Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsy-chotic medications. Am J Med. 2008;121:98-104.
30. Sakata T, Ookuma K, Fujimoto K, Fukagawa K, Yoshimat-su H. Histaminergic control of energy balance in rats. Brain Res Bull. 1991;27:371-375.
31. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsy-chotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358-363.
32. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374:542-546.
33. Gilles M, Wilke A, Kopf D, Nonell A, Lehnert H, Deuschle M. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics. Psy-chosom Med. 2005;67:748-751.
34. Ardizzone TD, Bradley RJ, Freeman AM, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotics drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 2001;923:82-90.
35. Bachelard HS, Lindsay JR. Effects of neurotropic drugs on glucose metabolism in rat brain in vivo. Biochem Pharmacol. 1966;15:1053-1058.
36. Larsson S. The effect of chlorpromazine on the glucose metabolism in different parts of the goat brain. Acta Physiol Scand. 1961;53:68-74.
37. Dwyer DS, Lu X-H, Freeman AM. Neuronal glucose metabolism and schizophrenia: therapeutic prospects? Expert Rev Neurother. 2003;3:29-40.
38. Robinson KA, Yacoub Wasef SZ, Buse MG. At therapeutic concentrations, olanzapine does not affect basal or insulinstimulated glucose transport in 3T3-L1 adipocytes. Prog Neu-ropsychopharmacol Biol Psychiatry. 2006;30:93-98.
39. Schaber G, Stevens I, Gaertner HJ, Dietz K, Breyer-Pfaff U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br J Clin Pharmacol. 1998;46:453-459.
40. Kassahun K, Mattiuz E, Nyhart E, Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25:81-93.
41. Wilner KD, Tensfeldt TG, Baris B, et al. Single and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol. 2000;49:15S-20S.